News Details - novonordisk.com
Sep 20, 2024 · Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 …
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
NVO. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1)...
Monlunabant phase 2a trial in obesity successfully completed
Sep 20, 2024 · Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 …
Novo Shares Fall on Safety Data for New Weight-Loss Drug - Bloomberg.com
Sep 20, 2024 · Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs. A mid-stage trial showed that monlunabant helped...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
Sep 20, 2024 · Based on the results, Novo Nordisk expects to initiate a larger phase 2b trial in obesity to further investigate dosing and the safety profile of monlunabant over a longer duration in a global...
Novo Nordisk A/S, Monlunabant phase 2a trial in obesity …
Sep 23, 2024 · Bagsvaerd, Denmark - Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 inverse agonist.
Novo Nordisk’s obesity newcomer monlunabant heads into …
Sep 20, 2024 · Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity. The trial showed significant weight loss with a 10 mg dose, achieving a 7.1 kg reduction versus 0.7 kg for placebo. Mild to …
Novo Nordisk Stock Declines After Headline Results From Mid …
Sep 20, 2024 · Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist....
Novo Nordisk (NVO): Monlunabant phase 2a trial in obesity …
Sep 20, 2024 · Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly...
Questions over Novo Nordisk $1bn weight loss drug after Phase …
Sep 23, 2024 · Novo Nordisk acquired monlunabant in a $1bn deal last year, but the Phase IIa trial raises questions over the efficacy and safety ratio.